<DOC>
	<DOCNO>NCT00180037</DOCNO>
	<brief_summary>This study design evaluate symptomatic effect Coenzyme Q10 nanodispersed solution middle-stage Parkinson 's disease ( PD ) patient ( Hoehn &amp; Yahr II III ) . The treatment phase include three month period 300 mg Coenzyme Q10 per day placebo . The primary outcome measure combine Unified Parkinson 's Disease Rating Scale ( UPDRS ) Part II III . The hypothesis study Coenzyme Q10 improve energy status diseased dopaminergic neuronal cell type thus produce dopamine lead improvement parkinsonian symptom PD patient .</brief_summary>
	<brief_title>Coenzyme Q10 Symptomatic Treatment Parkinson 's Disease</brief_title>
	<detailed_description>This study design evaluate symptomatic effect Coenzyme Q10 nanodispersed solution middle-stage non-fluctuating Parkinson 's disease ( PD ) patient ( Hoehn &amp; Yahr II III ) . The treatment phase include three month period 300 mg Coenzyme Q10 per day placebo . The design study prospective , randomize , multicenter , double-blind placebo-controlled protocol . The intervention include 100 mg Coenzyme Q10 nanodispersion ( Nanoquinon solution ) tid match placebo three month . Participating study center include Neurological University Outpatient Clinics Neurological Departments Community-based Hospitals experience PD patient . The primary outcome measure combine Unified Parkinson 's Disease Rating Scale ( UPDRS ) Part II III . The hypothesis study Coenzyme Q10 improve energy status diseased dopaminergic neuronal cell type thus produce dopamine lead improvement parkinsonian symptom PD patient . Main inclusion criterion : - Parkinson 's disease accord UK Brain Bank criterion - Hoehn &amp; Yahr stadium II III - Age 40 75 year - UPDRS Part III &gt; 15 point - No motor fluctuation dyskinesias - Stable medication 4 week prior inclusion Main exclusion criterion : - Atypical parkinsonian syndrome - Dyskinesias motor fluctuation - Coenzyme Q10 treatment past - Pregnancy</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Parkinson 's disease accord UK Brain Bank criterion Hoehn &amp; Yahr stadium II III Male female Age 40 75 year UPDRS Part III &gt; 15 point No motor fluctuation dyskinesias Stable parkinsonian condition 4 week prior inclusion Outpatients Patients without stable levodopa treatment 4 week prior inclusion Written inform consent Atypical druginduced parkinsonian syndrome Dyskinesias motor fluctuation Coenzyme Q10 treatment past Pregnancy Epileptic seizures history Hypothyroidism Severe medical condition interference study drug Treatment CSE inhibitor , thyroidal hormone , antiarrhythmic drug , warfarin , metformin Treatment intake vitamin , magnesium , vitamin E , calcium</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Coenzyme Q10</keyword>
	<keyword>Treatment</keyword>
	<keyword>Neuroprotection</keyword>
</DOC>